Search
forLearn
5 / 801 resultslearn retinoic acid
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn Celastrol
learn Calcipotriene
Research
5 / 30 resultsresearch Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
research A Case of Cicatricial Alopecia Associated with Erlotinib
Erlotinib can cause hair loss as a side effect.
research Scalp Pustule as a Manifestation of Erlotinib-Induced Skin Toxicity: Report of Two Cases and Literature Review
Erlotinib can cause scalp pustules and hair loss, needing early treatment with antibiotics and steroids.
research Abstract 4350: Pharmacodynamic biomarkers: Evaluation of oncology drug target engagement in human plucked scalp and beard hair
Plucked hair can effectively monitor drug effects in cancer treatment.
research Are all adverse effects undesirable? a case of chemotherapy induced adverse effect- an exception!?
Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
Community Join
5 / 1000+ resultscommunity Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
community Pyrilutamide kintor pharmaceutical
The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.
community Clascoterone - what we have right now
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
community Pyrilutamide Phase 3 on its way
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
community Trestolone (MENT) as a nuclear treatment
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.